|Bid||0.00 x 1000|
|Ask||286.18 x 800|
|Day's range||278.12 - 289.44|
|52-week range||268.62 - 380.76|
|Beta (3Y monthly)||1.20|
|PE ratio (TTM)||44.37|
|Earnings date||21 Oct 2019 - 25 Oct 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||322.57|
By buying an index fund, investors can approximate the average market return. But many of us dare to dream of bigger...
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
I've been keeping an eye on Illumina, Inc. (NASDAQ:ILMN) because I'm attracted to its fundamentals. Looking at the...
The genomic sequencing company reported slower revenue growth because of several issues, including a delay in closing a major population genomics deal.
Illumina (ILMN) delivered earnings and revenue surprises of 2.27% and 0.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Investing.com - Illumina (NASDAQ:ILMN) reported second quarter earnings that matched analysts' expectations on Monday and revenue that fell short of forecasts.
Illumina, GW Pharmaceuticals, Paycom, Zscaler and Square highlighted as Zacks Bull and Bear of the Day
Illumina is set to report its Q2 earnings on Monday, July 29 and investors are waiting to see if there is anything that might help the stock recover from its recent fall.
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.